BiotechTube
Britecyte

Britecyte

Seattle, United States· Est.
britecyte.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Britecyte is a private, Seattle-based biotech founded in 2016, developing regenerative therapies based on its proprietary platform for non-immunogenic allogeneic adipose tissue. The company has two initial commercial products, Liposana and Lipoderma, for soft tissue restoration, and is exploring pipeline applications in metabolic diseases and osteoarthritis. Operating as a therapeutics company, Britecyte appears to be in an early commercial or pre-revenue stage, leveraging its scientific breakthrough to create ready-to-use adipose allografts that overcome the limitations of autologous tissue transfer.

Metabolic DiseasesOsteoarthritisSoft Tissue ReconstructionAesthetic Medicine

Technology Platform

Proprietary platform for processing human adipose tissue to eliminate immunogenicity, creating ready-to-use, native allogeneic adipose tissue grafts free from synthetic agents.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The company addresses massive markets in aesthetic medicine, reconstructive surgery, and metabolic diseases with a first-in-class, off-the-shelf allogeneic adipose tissue product.
Success in its initial commercial products could provide proof-of-concept and revenue to fund development of its potentially transformative therapeutic pipeline for conditions like diabetes and osteoarthritis.

Risk Factors

Key risks include unproven long-term clinical efficacy and safety of the immunogenicity claim, a complex regulatory pathway for biologic tissue products, challenges in scaling manufacturing and ensuring tissue supply, and high scientific risk associated with transitioning from structural to metabolic therapeutic applications.

Competitive Landscape

In aesthetics, Britecyte competes with major dermal filler companies (Allergan, Galderma) and autologous fat grafting. In reconstruction, it competes with implants and autologous tissue transfer. Its allogeneic approach is novel. In therapeutics, it would be a pioneer; potential future competitors include other regenerative medicine companies developing cell-based therapies for metabolic disorders.

More companies in United States →